BioCentury | Jun 28, 2019
Translation in Brief

Banking on biomarkers for synthetic lethality

Repare thinks its biomarker-first approach could be a key differentiator for its synthetic lethal cancer drug programs. The company is collaborating with test developers ahead of time to recruit patients poised to benefit. Losing function...
BioCentury | Jun 7, 2019
Targets & Mechanisms

Following PARP, ATR axis next in line to expand synthetic lethal drug class

Promising ASCO readouts suggest targets in the ATR pathway are lining up behind PARP as the next drivers of “synthetic lethal” cancer killing. Biomarker and combination strategies presented at the American Society of Clinical Oncology...
BioCentury | Jun 1, 2019
Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

...data in 28 patients; dose-dependent changes in expression of target genes 3085 Bayer AG (Xetra:BAYN) BAY 1895344...
BioCentury | Apr 22, 2019
Distillery Therapeutics

Combining ATR inhibitors with chloroquine for PDAC

DISEASE CATEGORY: Cancer INDICATION: Pancreatic cancer Cell culture and mouse studies suggest inhibiting ATR and the autophagy inhibitor chloroquine could help treat pancreatic ductal adenocarcinoma (PDAC). Screening of protein kinase inhibitors in a human PDAC...
Items per page:
1 - 4 of 4